James Kirkland

Senior Vice President, Chief Financial Officer & Treasurer, Vector

Search every verified James Kirkland interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. James Kirkland, Senior Vice President, Chief Financial Officer & Treasurer at Vector, appeared in an interview at the Cold Spring Harbor Laboratory 89th Symposium on Quantitative Biology, where he discussed senolytics. He described senolytics as agents or approaches to selectively eliminate senescent cells, noting that many currently in clinical trials target tissue-damaging senescent cells. Kirkland stated that in the context of cancer, new classes of senolytics or alternating use with drugs called senosensitizers may be needed to eliminate all types of senescent cells, as they can harbor cancerous mutations. Kirkland said that senescent cells are highly variable, depending on the cell type, how senescence was induced, and the microenvironment. He noted that for age-related diseases, 30 to 70% of cells in the responsible tissue tend to be tissue-damaging and susceptible to senolytics. He also commented on the need for regulation of senolytic agents, advocating for good manufacturing practices, supervision by regulatory authorities such as the FDA or EMA, and use by healthcare professionals in an evidence-based manner. Kirkland mentioned that multiple clinical trials are being conducted simultaneously around the world for different indications, with a focus on serious life-threatening conditions lacking current treatments.